Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes - Eli Lilly

Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes  Eli LillyEli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial  CNBCLilly’s Retatrutide Shows Significant Improvement In Weight Loss and Blood Sugar  WSJLilly’s Experimental Diabetes Shot Yields Record Weight Loss in Study  Bloomberg.comEli Lilly’s ‘triple-G’ drug leads to significant blood sugar, weight reductions in diabetes trial  statnews.com